Sponsored by Institute of Chinese Pharmaceutical Association
ISSN 1001-5302 CN 11-2272/R
24 issues per year
Discipline(s): Medical Science
Current Issue: Issue 14, 2019
China Journal of Chinese Materia Medica, the 1st in the field of TCM, is supervised by China Association for Science and Technology and sponsored by Institute of Chinese Pharmaceutical Association. The journal is China's earliest comprehensive core journal of traditional Chinese medicine, and always maintains the circulation top in the professional areas. The journal publishes the latest research and progress of traditional Chinese medicine and takes a leading position in numbers of articles published, downloads and citations among all journals in this discipline. Its scope covers new achievements, technologies, methods, experiences and concepts resulting from the research on Chinese materia medica pursuant to Chinese medical and pharmaceutical theories, traditional experiences, and modern science and technology, including medicinal resources and identification, cultivation, processing, preparation, chemistry, pharmacology, theory of Chinese pharmacy and clinical practice, bencaological study. The journal is included in CA, JST and CSCD.
Zhang Boli, Hu Zhibi, Yao Xinsheng, Li Lianda, Li Dapeng, Yang Baofeng, Zhou Chaofan, Huang Luqi, Chen Shilin, Li He.
Executive Editorial Board
Cai Shaoqing, Chen Shilin
Efficacy and safety of Shenxiong Glucose Injection in treatment of cerebral thrombosis: systematic review and Meta-analysis
Vol 44,No. 14
To systematically evaluate the efficacy and safety of Shenxiong Glucose Injection in the treatment of cerebral thrombosis. Randomized controlled trials (RCTs) of Shenxiong Glucose Injection for cerebral thrombosis were screened out by searching CNKI, WanFang, VIP, SinoMed, Cochrane Library, PubMed, EMbase, and Web of Science in a systematic way, and the Meta-analysis on finally included studies was conducted by using Handbook 5.1 evaluation criteria and tools and RevMan 5.3 software. GRADE system (GRADE pro 3.6.1) was used to grade the evidence quality of key outcome indicators. A total of 25 studies were included, with a total sample size of 2 286 cases, 1 144 in the experimental group and 1 142 in the control group. The results of Meta-analysis showed that the total effective rate of Shenxiong Glucose Injection combined with ozagrel in the treatment of cerebral thrombosis was better than that of ozagrel alone (RR = 1.26, 95% CI [1.20, 1.32], P < 0.000 01); the total effective rate of conventional treatment plus Shenxiong Glucose Injection and ozagrel for cerebral thrombosis was better than that of conventional treatment combined with ozagrel (RR = 1.26, 95% CI [1.09, 1.46], P = 0.002). In addition, Shenxiong Glucose Injection combined with ozagrel could reduce the incidence of adverse reactions (RR = 0.38, 95% CI [0.24, 0.60], P < 0.000 1), improve the neurological impairment (MD 14 d = −7.19, 95% CI [−9.16, −5.22], P < 0.000 1; MD 30 d = −5.34, 95% CI [−5.85, −4.83], P < 0.000 1; MD 42 d = −7.03, 95% CI [−7.79, −6.28], P < 0.000 01; MD 60 d = −6.18, 95% CI [−6.55, −5.81], P < 0.000 01; MD 90 d = −4.90, 95% CI [−5.74, −4.06], P < 0.000 01), and improve activities of daily living (ADL) (MD = 15.00, 95% CI [12.20, 17.80], P < 0.000 01). The mortality was only included in one study, and the sample size was small, requiring to be further verified by a large sample size. The adverse reactions mainly included lung infection, skin pruritus, gastrointestinal reaction and so on, all of which could be tolerated or disappeared without affecting the treatment. Based on the available data and methods, Shenxiong Glucose Injection combined with ozagrel for cerebral thrombosis could improve the total effective rate, neurological impairment, and ability of daily living, with no serious adverse reactions. The evidence quality level of GRADE system was low in the evaluation of total effective rate, mortality and incidence of adverse reactions. However, the quality of the included researches was not high, requiring rigorously designed and internationally standardized clinical trials with a large sample size to improve the quality of evidence.
Vol 44,No. 14
To characterize the chemical constituents of Huanbei Zhike Prescription by ultra-high performance liquid chromatography-time of flight mass spectrometry (UPLC-Q-TOF-MS/MS). A Thermo Syncronls C 18 column (2.1 mm × 100 mm, 1.7 μm) was used with methanol (A) –0.1% formic acid solution (B) as the mobile phase for gradient elution. The injection volume was 2 μL. The column temperature was 40 °C. The flow rate was 0.3 mL·min −1. The electrospray ionization (ESI) source was used to collect data in positive and negative ion modes. The ion scanning range was at m/z 50–1 200, with capillary voltage at 3 000 V, ion source temperature at 100 °C, atomization gas flow rate at 50 L·h -1, desolvent gas flow rate at 800 L·h -1, desolvent temperature at 400 °C, and cone hole voltage at 40 V. The argon was used as the collision gas and the collision energy was 20–35 V. The excimer ion peak information was analyzed by Waters UNIFI data processing software. The molecular formula with error within 1 × 10 −5 was compared with the data in database to identify the compounds. The secondary fragment ion information of the target compound was selected, and then compared with the retention time and fragmentation patterns provided by the database and the existing literature to further confirm the compositions and structures of the compounds. A total of 68 main compounds in Huanbei Zhike Prescription were identified, including 38 flavonoids, 10 organic acids, 6 terpenoids, and 10 nitrogen-containing compounds, of which 12 compounds were verified by the control substances. This method is rapid and accurate, which provides a new strategy for the qualitative analysis of the chemical constituents of Huanbei Zhike Prescription, and lays a foundation for the further study and quality control of the pharmacodynamic substance in such prescription.